Proliferative index: Difference between revisions

Revision as of 12:35, 5 June 2018

Revision as of 17:39, 21 August 2018

Line 17:

== Diagnostic role of proliferation index ==

The various methods of characterizing the proliferation index have found roles in both the diagnostic and prognostic evaluation of tumors. For instances, the number of mitotic cells is used to classify tumors. In general, a high proliferation index suggests malignancy and [[Grading (tumors)|high-grade tumors]].<ref>{{Cite journal|last=Elston|first=C. W.|last2=Ellis|first2=I. O.|date=November 1991|title=Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up|journal=Histopathology|volume=19|issue=5|pages=403–410|issn=0309-0167|pmid=1757079}}</ref> Among solid tumors, the clinical significance of the proliferation index on breast cancer has been extensively studied. Mitotic counting has also been shown in multiple studies to have prognostic value in breast cancer, where a lower count of mitotic cells correlates with a more favorable outcome, and thus has been incorporated into part of the histological grading system. The Ki-67 labelling index has also been found to have prognostic significance where in many clinical practice guidelines, evaluation of Ki-67 in newly diagnosed invasive breast carcinomas is recommended.<ref>{{Cite journal|last=Dowsett|first=Mitch|last2=Nielsen|first2=Torsten O.|last3=A’Hern|first3=Roger|last4=Bartlett|first4=John|last5=Coombes|first5=R. Charles|last6=Cuzick|first6=Jack|last7=Ellis|first7=Matthew|last8=Henry|first8=N. Lynn|last9=Hugh|first9=Judith C.|date=2011-11-16|title=Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group|url=https://academic.oup.com/jnci/article/103/22/1656/890097|journal=JNCI Journal of the National Cancer Institute|language=en|volume=103|issue=22|pages=1656–1664|doi=10.1093/jnci/djr393|issn=0027-8874|pmc=3216967}}</ref> Additionally, the tumor proliferation index has been used to predict the response to systemic chemotherapies in patients who are receiving [[Neoadjuvant therapy|neoadjuvant]] systemic therapy where patients who have tumors with high tumor proliferative index respond better to systemic cytotoxic therapies than those who have tumors with a low tumor proliferative index.<ref>{{Cite journal|last=Groheux|first=David|last2=Biard|first2=L.|last3=Lehmann-Che|first3=J.|last4=Teixeira|first4=L.|last5=Bouhidel|first5=F. A.|last6=Poirot|first6=B.|last7=Bertheau|first7=P.|last8=Merlet|first8=P.|last9=Espié|first9=M.|date=2018-04-04|title=Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer|url=https://link.springer.com/article/10.1007/s00259-018-3998-z|journal=European Journal of Nuclear Medicine and Molecular Imaging|language=en|pages=1–10|doi=10.1007/s00259-018-3998-z|issn=1619-7070}}</ref>

==References==